Advertisement

Drug Safety

, Volume 42, Issue 10, pp 1149–1155 | Cite as

Evaluating Renal Stress Using Pharmacokinetic Urinary Biomarker Data in Critically Ill Patients Receiving Vancomycin and/or Piperacillin–Tazobactam: A Secondary Analysis of the Multicenter Sapphire Study

  • Sandra L. Kane-GillEmail author
  • Marlies Ostermann
  • Jing Shi
  • Emily L. Joyce
  • John A. Kellum
Short Communication

Abstract

Introduction

A drug combination that has gained recent attention for an additive risk of nephrotoxicity is vancomycin plus piperacillin–tazobactam. Clinicians need to better understand whether tubular cell stress occurs with piperacillin–tazobactam administration to establish whether renal injury associated with this combination is a valid clinical concern.

Objective

An evaluation of the pharmacokinetics of urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding-protein 7 (IGFBP7) for patients receiving vancomycin alone, piperacillin–tazobactam alone, and vancomycin plus piperacillin–tazobactam in combination was conducted to understand the impact on acute kidney cell stress and compare the rates of dialysis or death at 9 months among these three drug exposure types.

Methods

A secondary analysis of the prospective, multicenter Sapphire study (ClinicalTrials.gov identifier NCT01209169) including 35 intensive care units (ICUs) in North America and Europe was performed. Critically ill adult patients at risk for acute kidney injury (AKI) were included. Urinary [TIMP-2]∙[IGFBP7] was measured serially. Patients who received vancomycin alone, piperacillin–tazobactam alone, or vancomycin plus piperacillin–tazobactam were grouped according to their maximum AKI stage within 3 days of the first drug dose.

Results

Of 723 critically ill adults admitted to the ICU, 46% received either piperacillin–tazobactam (n = 110), vancomycin (n = 156), or both (n = 67). The urinary [TIMP-2]∙[IGFBP7] was highest on day 1 for the combination group. AKI stage 2/3 occurred more frequently in patients receiving the drug combination than in those receiving piperacillin–tazobactam alone (p = 0.03) but not vancomycin alone (p = 0.29). Risk of death or dialysis at 9 months was greatest for vancomycin plus piperacillin–tazobactam (48%) and similar for patients receiving vancomycin alone (29%) or piperacillin–tazobactam alone (35%) (p = 0.03 for unadjusted and p = 0.048 after adjusting for covariates).

Conclusion

After exposure to piperacillin–tazobactam and vancomycin in combination, there was a greater release of AKI biomarkers in patients who develop AKI than with piperacillin–tazobactam or vancomycin monotherapy and the combination is associated with possible increased long-term adverse outcomes.

Notes

Compliance with Ethical Standards

Funding

The Sapphire study was funded by Astute Medical, Inc. and they supported this secondary evaluation through resources for statistical analysis.

Conflict of interest

Sandra Kane-Gill, Marlies Ostermann, and Emily Joyce have no conflicts of interest that are directly relevant to the content of this study. Jing Shi has received consulting fees from Astute Medical, Inc. John Kellum has received grant support and consulting fees from Astute Medica, including licensing fees paid to the University of Pittsburgh by Astute Medical for unrelated technology.

Ethical approval

The Sapphire study was approved by the Western Institutional Review Board (Olympia, WA, USA) and individual review boards or ethics committees as required by each study site.

Informed consent

All subjects or authorized representatives provided written informed consent.

Supplementary material

40264_2019_846_MOESM1_ESM.docx (34 kb)
Supplementary material 1 (DOCX 33 kb)
40264_2019_846_MOESM2_ESM.docx (26 kb)
Supplementary material 2 (DOCX 25 kb)
40264_2019_846_MOESM3_ESM.docx (6.7 mb)
Supplementary material 3 (DOCX 5085 kb)
40264_2019_846_MOESM4_ESM.docx (27 kb)
Supplementary material 4 (DOCX 27 kb)

References

  1. 1.
    Rivosecchi RM, Kellum JA, Dasta JF, Armahizer MJ, Bolesta S, Buckley MS, et al. Drug class combination-associated with acute kidney injury. Ann Pharmacother. 2016;50:953–72.CrossRefPubMedGoogle Scholar
  2. 2.
    Luther MK, Timbrook TT, Caffrey R, Dosa D, Lodise TP, LaPlante KL. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2018;46:12–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Rutter WC, Burgess DS. Acute kidney injury in patients treated with IV beta-lactam/beta-lactamase inhibitor combinations. Pharmacotherapy. 2017;37:593–8.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57:734–44.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Luque Y, Lousi K, Jouanneau C, Placier S, Esteve E, Bazin D, et al. Vancomycin-associated cast nephropathy. J Am Soc Nephrol. 2017;28:1723–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Pai MP, Neely M, Rodviod KT, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014;20:50–7.CrossRefGoogle Scholar
  7. 7.
    Carreno J, Smiraglia T, Hunter C, Tobin E, Lomaestro B. Comparative incidence and excess risk of acute kidney injury in hospitalized patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy. Int J Antimicrob Agents. 2018;52:643–50.CrossRefPubMedGoogle Scholar
  8. 8.
    Gomes DM, Smotherman C, Birch A, Dupree L, Della Vecchia BJ, Kraemer DF, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy. 2014;34:662–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Navalkele B, Pogue JM, Karine S, Nishan B, Salim M, Solanki S, et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime. Clin Infect Dis. 2017;64:116–23.CrossRefPubMedGoogle Scholar
  10. 10.
    Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JB, Holzgrabe U, Sorgetl F. Inhibition of flucloxacillin tubular renal secretion by piperacillin. Br J Clin Pharmacol. 2008;66:648–59.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Kashani K, Al-khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17:R25.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kane-Gill SL, Smithburger PL, Kashani K, Kellum JA, Frazee E. Clinical relevance and predictive value of damage biomarkers of drug-induced kidney injury. Drug Saf. 2017;40:1049–74.CrossRefPubMedGoogle Scholar
  13. 13.
    Ostermann M, McCullough PA, Lorni LG, Bagshaw SM, Joannidis M, Shi J, et al. Kinetics of urinary cell cycle arrest markers for acute kidney injury following exposure to potential renal insults. Crit Care Med. 2018;46:375–83.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;14:204.CrossRefGoogle Scholar
  15. 15.
    Pajenda S, Ilhan-Mutlu A, Preusser M, Roka S, Druml W, Wagner L. NephroCheck data compared to serum creatinine in various clinical settings. BMC Nephrol. 2015;16:206.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Schneider AG, Lipcsey M, Bailey M, Pilcher DV, Bellomo R. Relationship between illness severity scores and acute kidney injury. Crit Care Resusc. 2012;14:53–5.PubMedGoogle Scholar
  17. 17.
    Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother. 2011;55:3278–83.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Astute Medical, Inc., Evaluation of novel biomarkers from acutely ill patients at risk for acute kidney injury [ClinicalTrials.gov identifier NCT01209169]. US National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 17 Jun 2019

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.School of PharmacyUniversity of PittsburghPittsburghUSA
  2. 2.Center for Critical Care Nephrology, University of PittsburghPittsburghUSA
  3. 3.Department of Critical Care MedicineUniversity of PittsburghPittsburghUSA
  4. 4.Department of Critical CareKing’s College London, Guy’s and St Thomas’ HospitalLondonUK
  5. 5.Department of BiostatisticsWalker BioscienceCarlsbadUSA
  6. 6.Department of Pediatrics (Nephrology)University of PittsburghPittsburghUSA
  7. 7.UPMC Children’s HospitalPittsburghUSA

Personalised recommendations